Recursion Pharmaceuticals is a clinical-stage biotech that industrializes drug discovery by combining automated high-throughput biology experiments with machine learning. Its platform generates large proprietary datasets of cellular images and other measurements to map biology and identify candidates across many disease areas. The company partners with larger pharmaceutical firms while also advancing its own pipeline in areas such as rare disease, oncology and fibrosis-related indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 14.8 | — | -202.5 | — |
| Q2 2025 | 19.1 | — | -171.9 | — |
| Q3 2025 | 5 | — | -162.3 | — |
| Q4 2025 | 35.4 | — | -108.1 | — |
| Q1 2026 | 6.3 | -57.5% | -117.5 | — |
| Q2 2026 | 7.3 | -61.8% | -131 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: OceanFirst Financial Corp. (OCFC), Surgery Partners, Inc. (SGRY), Pagaya Technologies Ltd. (PGY), BioLife Solutions, Inc. (BLFS), The Goodyear Tire & Rubber Company (GT), Braveheart Bio, Inc. (BRVE)